Most Recent Publications
Sci Transl Med. 2021 Oct 13. [Epub ahead of print]
MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases
Nucl Med Biol. Jan-Feb 2020;80-81:37-44.
Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [111In]In-Bn-DTPA-nimotuzumab in mice with triple-negative or trastuzumab-resistant human breast cancer xenografts that overexpress EGFR
EJNMMI Radiopharm Chem. 2019 Oct 11;4(1):27.
Auger electrons for cancer therapy - a review.
Mol Pharm. 2019 Aug 5;16(8):3559-3568.
MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with 99mTc(I) Tricarbonyl Complex.
J Nucl Med. 2019 Jul;60(7):899-901.
Immuno-PET to Optimize the Dose of Monoclonal Antibodies for Cancer Therapy: How Much Is Enough?
Mol Pharm. 2019 Feb 4;16(2):768-778.
Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelating Polymers Complexed to 177Lu.
Medical Imaging for Health Professionals: Technologies and Clinical Applications
Constantine Georgiou received the MDS Nordion Graduate Scholarship in Radiopharmaceutical Sciences.
Anthony Ku received the Queen Elizabeth II Graduate Scholarship in Science and Technology (QEII-GSST) 2019 and the Center of Pharmaceutical Sciences Scholarship 2019.
Valerie Facca received the scholarship of the Strategic Training in Transdisciplinary Radiation Science for the 21st Century (STARS21) Program of the 2019-2020 session.
Congratulations to Professor Raymond Reilly on receiving the Brain Tumour Foundation of Canada grant to develop radiation nanomedicine agents for the treatment of glioblastoma multiforme.
Congratulations to Noor Al-saden on receiving the PRiME postdoctoral fellowship to investigate a new radiation nanomedicine agents for the treatment of glioblastoma multiforme.
Canadian Cancer Society Research Institute Innovation to impact Grant, July 2019
Professor Raymond Reilly receives Canadian Cancer Society Innovation to Impact grant to study a new radiation treatment (NanoRad) for triple-negative breast cancer (TNBC) based on radiolabeled gold nanoparticles.